PUBLICATIONS

2017

Paving the road to personalized medicine: Recommendations on regulatory, intellectual property and reimbursement challengesJournal of Law and the Biosciences. https://doi.org/10.1093/jlb/lsx030

Opportunities and challenges for the cellular immunotherapy sector: A global landscape of clinical trialsRegenerative Medicine. doi: 10.2217/rme-2017-0031

Creating a data resource: What will it take to build a medical information commonsGenome Medicine. doi: 10.1186/s13073-017-0476-3

A blueprint for the next generation of ELSI research, training, and outreach in regenerative medicineRegenerative Medicine. doi: 10.1038/s41536-017-0026-z

Marketing of unproven stem cell–based interventions: A call to actionScience Translational Medicine. doi: 10.1126/scitranslmed.aag0426

The sIRB system: A single beacon of progress in the revised Common Rule? The American Journal of Bioethicshttp://dx.doi.org/10.1080/15265161.2017.1328530

The ethics of genome editing in the clinic: A dose of realism for healthcare leadersHealthcare Management Forumhttps://doi.org/10.1177/0840470416689313 

More haste, less speed: Could public private partnerships advance cellular immunotherapies? Frontiers in Medicine. doi: 10.3389/fmed.2017.00134

Responsible translation of stem cell research: An assessment of clinical trial registration and publicationsStem Cell Reportshttp://dx.doi.org/10.1016/j.stemcr.2017.03.013

Discounting the recommendations of the second panel on cost-effectiveness in health and medicinePharmacoEconomicsdoi: 10.1007/s40273-016-0482-0

Non-invasive prenatal testing and the unveiling of an impaired translation processJournal of Obstetrics and Gynaecology Canadadoi: 10.1016/j.jogc.2016.09.004

Consider drug efficacy before first-in-human trialsNature. doi: 10.1038/542025a

Show drugs work before selling themNature. doi: 10.1038/543174a

The health economics for regenerative medicine: How payers think and what that means for developers (book chapter). “Mesenchymal Stromal Cells: Translational Pathways to Clinical Adoption.” https://doi-org.login.ezproxy.library.ualberta.ca/10.1016/B978-0-12-802826-1.00011-8

Determinants of change in the cost-effectiveness thresholdMedical Decision Makinghttps://doi.org/10.1177/0272989X16662242

2016

Streamlining ethical review of data intensive researchBMJ. http://www.bmj.com/content/354/bmj.i4181

How mutually recognizable is mutual recognition? An international terminology index of research ethics review policies in the USA, Canada, UK and AustraliaPersonalized Medicine. http://www.futuremedicine.com/doi/pdf/10.2217/pme.15.52

Ethics review for international data-intensive researchScience. http://science.sciencemag.org/content/351/6280/1399.full